Ken Herrmann1, Constantin Lapa2, Hans-Juergen Wester3, Margret Schottelius4, Christiaan Schiepers5, Uta Eberlein2, Christina Bluemel2, Ulrich Keller6, Stefan Knop7, Saskia Kropf8, Andreas Schirbel2, Andreas K Buck2, Michael Lassmann2. 1. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California Herrmann_K1@ukw.de. 2. Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. 3. Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany Scintomics GmbH, Fürstenfeldbruck, Germany. 4. Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany. 5. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California. 6. III. Medical Department of Hematology and Medical Oncology, Technische Universität München, Munich, Germany; and. 7. Division of Hematology and Medical Oncology, Department of Internal Medicine II, Universitätsklinikum Würzburg, Würzburg, Germany. 8. Scintomics GmbH, Fürstenfeldbruck, Germany.
Abstract
UNLABELLED: (68)Ga-pentixafor is a promising PET tracer for imaging the expression of the human chemokine receptor 4 (CXCR4) in vivo. The whole-body distribution and radiation dosimetry of (68)Ga-pentixafor were evaluated. METHODS: Five multiple-myeloma patients were injected intravenously with 90-158 MBq of (68)Ga-pentixafor (mean ± SD, 134 ± 25 MBq), and a series of 3 rapid multiple-bed-position whole-body scans were acquired immediately afterward. Subsequently, 4 static whole-body scans followed at 30 min, 1 h, 2 h, and 4 h after administration of the radiopharmaceutical. Venous blood samples were obtained. Time-integrated activity coefficients were determined from multiexponential regression of organ region-of-interest data normalized to the administered activity, for example, the time-dependent percentages of the injected activity per organ. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. RESULTS: The effective dose based on 150 MBq of (68)Ga-pentixafor was 2.3 mSv. The highest organ-absorbed doses (for 150 MBq injected) were found in the urinary bladder wall (12.2 mGy), spleen (8.1 mGy), kidneys (5.3 mGy), and heart wall (4.0 mGy). Other organ mean absorbed doses were as follows: 2.7 mGy, liver; 2.1 mGy, red marrow; 1.7 mGy, testes; and 1.9 mGy, ovaries. CONCLUSION: (68)Ga-pentixafor exhibits a favorable dosimetry, delivering absorbed doses to organs that are lower than those delivered by (18)F-FDG- or (68)Ga-labeled somatostatin receptor ligands.
UNLABELLED: (68)Ga-pentixafor is a promising PET tracer for imaging the expression of the human chemokine receptor 4 (CXCR4) in vivo. The whole-body distribution and radiation dosimetry of (68)Ga-pentixafor were evaluated. METHODS: Five multiple-myelomapatients were injected intravenously with 90-158 MBq of (68)Ga-pentixafor (mean ± SD, 134 ± 25 MBq), and a series of 3 rapid multiple-bed-position whole-body scans were acquired immediately afterward. Subsequently, 4 static whole-body scans followed at 30 min, 1 h, 2 h, and 4 h after administration of the radiopharmaceutical. Venous blood samples were obtained. Time-integrated activity coefficients were determined from multiexponential regression of organ region-of-interest data normalized to the administered activity, for example, the time-dependent percentages of the injected activity per organ. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. RESULTS: The effective dose based on 150 MBq of (68)Ga-pentixafor was 2.3 mSv. The highest organ-absorbed doses (for 150 MBq injected) were found in the urinary bladder wall (12.2 mGy), spleen (8.1 mGy), kidneys (5.3 mGy), and heart wall (4.0 mGy). Other organ mean absorbed doses were as follows: 2.7 mGy, liver; 2.1 mGy, red marrow; 1.7 mGy, testes; and 1.9 mGy, ovaries. CONCLUSION: (68)Ga-pentixafor exhibits a favorable dosimetry, delivering absorbed doses to organs that are lower than those delivered by (18)F-FDG- or (68)Ga-labeled somatostatin receptor ligands.
Authors: C Rischpler; S G Nekolla; H Kossmann; R J Dirschinger; M Schottelius; F Hyafil; H J Wester; K L Laugwitz; M Schwaiger Journal: J Nucl Cardiol Date: 2015-12-14 Impact factor: 5.952
Authors: Carsten Kobe; Ronald Boellaard; Jürgen Wolf; Georg Kuhnert; Markus Dietlein; Bernd Neumaier; Alexander Drzezga; Deniz Kahraman Journal: J Thorac Dis Date: 2015-12 Impact factor: 2.895
Authors: Dustin Wayne Demoin; Masahiro Shindo; Hanwen Zhang; Kimberly J Edwards; Inna Serganova; Naga Vara Kishore Pillarsetty; Jason S Lewis; Ronald G Blasberg Journal: Nucl Med Biol Date: 2016-05-14 Impact factor: 2.408
Authors: Christina Bluemel; Markus Krebs; Bülent Polat; Fränze Linke; Matthias Eiber; Samuel Samnick; Constantin Lapa; Michael Lassmann; Hubertus Riedmiller; Johannes Czernin; Domenico Rubello; Thorsten Bley; Saskia Kropf; Hans-Juergen Wester; Andreas K Buck; Ken Herrmann Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: Rudolf A Werner; Matthias Kroiss; Masatoyo Nakajo; Dirk O Mügge; Stefanie Hahner; Martin Fassnacht; Andreas Schirbel; Christina Bluemel; Takahiro Higuchi; Laszló Papp; Norbert Zsótér; Andreas K Buck; Ralph A Bundschuh; Constantin Lapa Journal: Endocrine Date: 2016-05-02 Impact factor: 3.633